Chemical Compound Review:
LAZEBEMIDE N-(2-aminoethyl)-5-chloro- pyridine-2...
Synonyms:
Lazabemide, CHEMBL279390, SureCN121998, CCRIS 7301, CHEBI:121860, ...
- Safety study of lazabemide (Ro19-6327), a new MAO-B inhibitor, on cardiac arrhythmias and blood pressure of patients with Parkinson's disease. Narabayashi, H., Yamaguchi, T., Sugi, K., Mitamura, H., Mizuno, Y., Nakashima, M. Clinical neuropharmacology. (1999)
- Short review on monoamine oxidase and its inhibitors. Kanazawa, I. Eur. Neurol. (1994)
- Lazabemide, a selective, reversible monoamine oxidase B inhibitor, as an aid to smoking cessation. Berlin, I., Aubin, H.J., Pedarriosse, A.M., Rames, A., Lancrenon, S., Lagrue, G. Addiction (2002)
- Lazabemide for the treatment of Alzheimer's disease: rationale and therapeutic perspectives. Cesura, A.M., Borroni, E., Gottowik, J., Kuhn, C., Malherbe, P., Martin, J., Richards, J.G. Advances in neurology. (1999)
- Selective and potent monoamine oxidase type B inhibitors: 2-substituted 5-aryltetrazole derivatives. Lebreton, L., Curet, O., Gueddari, S., Mazouz, F., Bernard, S., Burstein, C., Milcent, R. J. Med. Chem. (1995)
- Antioxidant activity of the monoamine oxidase B inhibitor lazabemide. Mason, R.P., Olmstead, E.G., Jacob, R.F. Biochem. Pharmacol. (2000)
- In vitro effects on monoamine uptake and release by the reversible monoamine oxidase-B inhibitors lazabemide and N-(2-aminoethyl)-p-chlorobenzamide: a comparison with L-deprenyl. Bondiolotti, G.P., Galva, M.D., Villa, F., Sciaba, L., Picotti, G.B. Biochem. Pharmacol. (1995)
- Pharmacokinetics and pharmacodynamics of single and multiple doses of the MAO-B inhibitor lazabemide in healthy subjects. Dingemanse, J., Wood, N., Jorga, K., Kettler, R. British journal of clinical pharmacology. (1997)
- Investigation on the structure of the active site of monoamine oxidase-B by affinity labeling with the selective inhibitor lazabemide and by site-directed mutagenesis. Cesura, A.M., Gottowik, J., Lahm, H.W., Lang, G., Imhof, R., Malherbe, P., Röthlisberger, U., Da Prada, M. Eur. J. Biochem. (1996)
- The activity of MAO A and B in rat renal cells and tubules. Guimarães, J.T., Soares-da-Silva, P. Life Sci. (1998)
- The density of monoamine oxidase B sites is not altered in the postmortem brain of alcoholics. Maeztu, A.I., Ballesteros, J., Callado, L.F., Gutiérrez, M., Meana, J.J. Alcohol. Clin. Exp. Res. (1997)
- Locomotor effects of imidazoline I2-site-specific ligands and monoamine oxidase inhibitors in rats with a unilateral 6-hydroxydopamine lesion of the nigrostriatal pathway. Macinnes, N., Duty, S. Br. J. Pharmacol. (2004)
- Differential substrate specificity of monoamine oxidase in the rat heart and renal cortex. Guimarães, J.T., Vindis, C., Soares-da-Silva, P., Parini, A. Life Sci. (2003)
- Determination of Ro 19-6327 (Lazabemide) in human plasma and urine by gas chromatography-negative chemical ionization mass spectrometry. Davis, P.P., Crews, T., Bradford, J.J., Edom, R.W. J. Chromatogr. B, Biomed. Appl. (1995)
- Increased density of catalytic sites and expression of brain monoamine oxidase A in humans with hepatic encephalopathy. Mousseau, D.D., Baker, G.B., Butterworth, R.F. J. Neurochem. (1997)
- Inhibition of monoamine oxidase modulates the behaviour of semicarbazide-sensitive amine oxidase (SSAO). Fitzgerald, D.H., Tipton, K.F. Journal of neural transmission (Vienna, Austria : 1996) (2002)